Microbot Medical secures FDA clearance for endovascular surgical robot - The Robot Report

Microbot Medical has received FDA 510(k) clearance for its Liberty endovascular surgical robot, marking it as the first FDA-cleared single-use, remotely operated robotic system designed for peripheral endovascular procedures. This clearance enables Microbot to commercialize Liberty in the U.S., targeting the approximately 2.5 million annual peripheral vascular procedures. The Liberty pivotal study demonstrated a 100% success rate in robotic navigation to target sites, zero device-related adverse events, and a significant 92% reduction in radiation exposure for physicians, highlighting its potential to improve procedural safety and efficiency. Liberty offers a compact, single-use solution that allows interventional physicians to perform neurovascular, cardiovascular, and peripheral vascular procedures remotely, aiming to enhance precision and reduce costs. Microbot also recently secured a patent for a modular robotic surgical system, which could allow future adaptations of Liberty to a broader range of endovascular procedures. With 12 patents granted globally and 57 pending, Microbot is positioning itself to expand its robotic